Beacon Medical-B (02170.HK) announced that the company's revenue increased by 45.8% to 12.47 million RMB for the six months ended June 30, 2024. The increase is mainly due to (i) the inclusion of Singapore BMX's financial performance in the company's global sales performance after the acquisition of Singapore BMX; and (ii) the steady growth in sales of core products in the company's five major laboratory scenarios. The sales of PGT reagent kits, embryo culture boxes, and ultra-low temperature storage products have achieved expected growth.
The group's gross profit increased by 72.3% to 5.79 million RMB for the six months ended June 30, 2024. The group's overall gross margin increased from 39.2% for the six months ended June 30, 2023 to 46.4% for the six months ended June 30, 2024, mainly due to the optimization of the product portfolio and the improvement of the overall gross margin as a result of the acquisition of Singapore BMX.
As of June 30, 2024, the company has registered 118 patents, 125 trademarks, 57 software copyrights, and 16 domain names in China. The company has also registered four trademarks in Hong Kong, one trademark in the United States, and one trademark in Japan. As of the same day, the company has submitted 65 patent applications in China.